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A commentary on
Far red/near infrared light-induced pro-
tection against cardiac ischemia and
reperfusion injury remains intact under
diabetic conditions and is independent of
nitric oxide synthase
by Keszler, A., Brandal, G., Baumgardt,
S., Ge, Z.-D., Pratt, P., Riess, M. L.,
et al. (2014). Front. Physiol. 5:305. doi:
10.3389/fphys.2014.00305
Ischemic heart disease is a major pub-
lic health epidemic and a leading cause
of morbidity and mortality worldwide
(Hausenloy et al., 2012; Ferdinandy
et al., 2014). Ischemic injury predisposes
to myocardial infarction, heart failure,
arrhythmias, and sudden cardiac death.
Prompt restoration of oxygenated blood
flow to the ischemic myocardium (i.e.,
reperfusion) is required for prevent-
ing irreversible cell damage and death.
Unfortunately, restoration of blood flow,
in itself, results in additional cardiac dam-
age, known as reperfusion injury. Such
oxidative damage, which is mediated by
bursts of reactive oxygen species (ROS),
is more severe when reperfusion therapy
is delayed. Indeed, necrotic cell death as
a consequence of ROS overproduction
can paradoxically exacerbate the extent
of myocardial infarction. Concomitantly,
reperfusion-mediated cytosolic calcium
overload and redox imbalance pro-
mote mechanoelectrical dysfunction and
arrhythmias.
In recent years, mitochondria have
emerged as central mediators of cell
death and survival pathways (O’Rourke
et al., 2005). On the one hand, opening
of energy-dissipating mitochondrial chan-
nels that destabilize the mitochondrial
membrane potential, such as the per-
meability transition pore (PTP) and the
inner membrane anion channel (IMAC),
result in myocardial infarction (Hausenloy
et al., 2012) and arrhythmias (Akar
et al., 2005), respectively. On the other
hand, the seminal discovery of intrin-
sic cardioprotective pathways that stem
from a mitochondrial origin has provided
hope for combatting ischemia-reperfusion
injury along with its pathological mani-
festations (impaired contractile recovery,
arrhythmias, and myocardial infarction)
(Murry et al., 1986). In particular, the
proven efficacy of ischemic pre- and post-
conditioning protocols in limiting the
damage imposed by the index ischemic
event has provided researchers with an
effective tool for uncovering endogenous
cardioprotective signaling pathways, with
the promise of identifying molecular tar-
gets that can be manipulated pharmaco-
logically (Ferdinandy et al., 2014).
Prominent amongst such targets are
ATP-sensitive potassium channels in
the mitochondrial membrane (mKATP)
which are tightly regulated by PKC sig-
naling. Although the molecular identity
of these channels has eluded discov-
ery for many years, recent work by
the O’Rourke laboratory convincingly
points to ROMK as a viable candidate
(Foster et al., 2012). Nonetheless mKATP
activation by diazoxide is cardioprotec-
tive against ischemia-reperfusion injury.
Another key target is the PTP whose open-
ing represents a terminal event that causes
necrotic cell death. Indeed, Hausenloy and
others have shown that PTP inhibition
using cyclosporine-A (CsA) effectively
limits the extent of myocardial infarc-
tion (Hausenloy et al., 2012). Whether
CsA protects or exacerbates post-ischemic
electrical dysfunction, however, remains
a matter of debate. This issue may be
complicated by PKC-dependent cross-talk
between the PTP and mKATP channels
which we recently examined (Xie et al.,
2014). Moreover, post-ischemic arrhyth-
mias can be suppressed by stabilizing the
mitochondrial membrane potential using
antagonists of the peripheral benzodi-
azepine receptor which modulates IMAC
(Akar et al., 2005). The efficacy of this
strategy in limiting infarct size, however,
has not been systematically tested. Finally,
volatile anesthetics have also been shown
to reduce reperfusion injury likely by tar-
geting mitochondrial pathways (Agarwal
et al., 2014). Because pharmacological
therapies for reperfusion injury have
proven difficult, novel approaches for this
epidemic are much needed.
In this issue of the journal, Keszler
et al. (2014) focused on a highly inno-
vative non-pharmacological strategy.
Specifically, they were able to harness
the power of near-infrared (NIR) light-
emitting diodes (LEDs) to liberate nitric
oxide (NO) in a manner that exerted
a potent cardioprotective effect. The
findings of Keszler et al. (2014) are excit-
ing on several grounds. Not only did
these authors expand our understanding
of the mechanism by which NIR elic-
its cardioprotection, they convincingly
documented its utility in the setting of
diabetes mellitus. This achievement can-
not be overstated given the failure of
most other cardioprotective strategies,
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including ischemic conditioning, in this
setting.
“NO” LIBERATION BY LIGHT
NIR light has been used to protect neu-
rons from methanol toxicity, stimulate
angiogenesis, heal chemotherapy-induced
mucositis, and reduce myocardial infarct
size throughNO-dependent signaling. The
beneficial role of NO is documented by
studies in which its inhibition was found
to abrogate the cardioprotective effects
of ischemic preconditioning. Moreover,
several agents known to increase NO
bioavailability (for example, phosphodi-
esterase inhibitors, glycerol trinitrate, and
nicorandil) are all potent activators of car-
dioprotective signaling. Of note, NO trig-
gers mKATP channel activation through
a PKG-cGMP dependent pathway, whose
protective effects are abolished by PKG
inhibitors or NO scavengers (Costa et al.,
2008). Moreover, NO reduces mitochon-
drial ROS levels and oxidative stress dur-
ing IR injury by trapping superoxide and
eliciting conformational changes that pro-
mote S-nitrosation of Complex I of the
electron transport chain (Wink et al., 1993;
Paolocci et al., 2001; Chouchani et al.,
2013). As such, NO markedly attenuates
ROS-mediated toxicity while elevated ROS
levels act to suppress basal and agonist-
induced NO release (Wink et al., 1993;
Paolocci et al., 2001).
Nitric Oxide Synthases (NOS), the
major enzymes that produce NO,
are upregulated in response to pre-
conditioning stimuli. Since NOS are
functionally downregulated in the context
of diabetes mellitus, the cardioprotective
signaling pathways that are elicited by NO
are severely compromised in this setting.
To circumvent this important limitation,
various groups have developed a clever
strategy for liberating NO directly from
heme-containing proteins using NIR light.
The utility of this strategy in diabetes,
however, remained largely unknown—at
least until now.
In an elegant Research Topic
(http://journal.frontiersin.org/ResearchTo
pic/1809) hosted by Aon and colleagues,
Keszler et al. (2014) demonstrated that
NIR-mediated cardioprotection, which
is likely to be NO-dependent (Lohr
et al., 2009), was surprisingly NOS-
independent. Treatment of hearts with
the NOS inhibitor L-NAME did not
significantly alter the extent of pro-
tection as the reduction in infarct size
remained virtually unchanged. Likewise,
the infarct-sparing effects of NIR were
neither abolished in endothelial NOS defi-
cient mice nor in a well-established model
of type-2 diabetes mellitus (db/db mice).
The exciting findings of Keszler et al.
(2014) should spur investigators to
examine the potential cardioprotective
efficacy of NIR as a tool for remote pre-
conditioning. If NIR is indeed effective
even when applied to remote areas and/or
organs, its clinical applicability and trans-
latability would be markedly enhanced.
Given the short half-life and high reactivity
of NO, the maximum allowable distance
between the site of NIR application and
the infarct location should be carefully
determined in future studies. Finally, since
NO signaling modulates numerous cellu-
lar targets, including a host of sarcolemmal
ion channels and calcium regulatory pro-
teins, it will be critical to investigate the
effects of NIR on electrophysiological
properties and excitation-contraction
coupling. As elegantly highlighted in
this Research Topic, NIR is promising
in its ability to treat diabetic hearts, for
which classically cardioprotective thera-
pies have failed. Indeed, the findings of
Keszler et al. (2014) break new grounds
in our effort to manage diabetic patients
who are at high risk of ischemia-related
complications.
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